bioRxiv Science⌕ Search

Biology subjects

Sullivan, M. O.

Publications and source records attributed to Sullivan, M. O..

3 recordsLinked to original sources

Commensal Engineered Living Materials for Sustained Secretome Delivery and Wound Healing

Using living cells as dynamic biological factories offers immense potential for the continuous, localized production of therapeutic proteins within compromised tissues. This strategy is particularly compelling for treating chronic non-healing wounds, which lack therapeutics that are able to function effectively in the inflammatory microenvironment. Commensal bacteria have been shown to promote healing in these hostile microenvironments, yet applying live microbes directly onto compromised tissue is clinically unfeasible due off-target safety risks and engraftment challenges. Herein, we establish a well-defined commensal Engineered Living Material (cELM) that allows encapsulation, retention, function, and delivery of native beneficial bacteria for localized production and release of a pro-healing secretome over weeks. We specifically encapsulated a pro-healing human wound bacterial isolate, Alcaligenes faecalis, using biocompatible, click-reactive hydrogel building blocks (thiol- or vinyl-sulfone-functionalized multi-arm poly(ethylene glycol)) and systematically varied the density of the polymer network and of the encapsulated bacteria to establish design rules for creating pro-healing cELMs. Physical confinement in the hydrogel network ensured bacterial biocontainment, while the hydrogel mesh size still permitted diffusion of the therapeutic secretome. Notably, controlling encapsulation density revealed an inverse relationship wherein lower cell densities yielded significantly enhanced per-cell metabolic activity and provided sustained production of pro-healing secreted factors. In a murine diabetic wound model, these A. faecalis cELMs shielded the encapsulated bacteria from host clearance, maintained biocontainment, accelerated re-epithelialization, and improved wound bed maturity. Together, these findings establish design principles for cELMs that couple bacterial biocontainment with sustained secretome delivery, providing a promising platform for localized treatment of chronic wounds.

bioengineering↗

Peptide additives reprogram the lipid nanoparticle corona and enhance gene delivery in a serum-free environment for lung epithelium

Lipid nanoparticles (LNPs) have become a clinical standard for systemically-administered nucleic acid drugs and vaccines, but the LNP pipeline for locally-delivered LNP therapies remains much less mature. Local delivery in lung represents a particularly compelling application space for DNA-LNP therapeutics, as local gene therapies could support sustained epithelial recovery and functional restoration in various lung diseases. However, locally-delivered DNA-LNPs face multiple barriers, including the limited availability of serum components that often support conventional LNP activity, and the additional delivery barriers posed by the nucleus. We generated hybrid peptide-lipid nanoparticles (hpLNPs) for pulmonary DNA delivery by using a core-shell assembly strategy to incorporate short histone-derived peptides, selected for their DNA-transport capacity, into a clinically inspired LNP formulation. In parallel, we evaluated serum pre-coating of LNPs as a strategy to boost hpLNP activity in the serum-poor airway environment. A peptide:DNA amine/phosphate (N/P) ratio of 0.9 was identified as the highest feasible ratio to permit peptide incorporation into hpLNPs while preserving DNA encapsulation efficiency at >90%, retaining hpLNP colloidal stability, and preserving the overall pKa for LNPs. At N/P = 0.9, hpLNPs showed markedly enhanced DNA delivery in alveolar lung cells, achieving up to a 17-fold increase in transgene expression compared to peptide-free LNPs. Transgene expression levels varied depending on serum concentration, with expression peaking in the presence of 6% serum. Furthermore, serum pre-coating was necessary to enable in vivo hpLNP activity following intratracheal administration in mice, yielding robust local GFP expression. Mechanistic studies in exosome-free serum revealed that peptide incorporation in the hpLNPs enhanced transgene delivery by increasing nanoparticle interactions with serum exosome components, resulting in significant enhancements to hpLNP uptake. Together, these findings identify nanoparticle- serum interactions as a critical determinant of LNP-mediated pulmonary DNA delivery and establish peptide incorporation and serum pre-coating as promising strategies to enable robust, localized gene transfer in serum-free environments.

bioengineering↗

A kinetic modeling platform for predicting the efficacy of siRNA formulations in vitro and in vivo

We present a computational modeling protocol that can accurately predict changes in both in vitro and in vivo gene expression levels in response to the application of various siRNA formulations. Users can obtain crucial information (i.e., maximum silencing level; duration of silencing) towards the design of therapeutically relevant dosing regimens with experimental measurements from a single time point as an input. This ability to simulate numerous experimental gene silencing scenarios has not been demonstrated previously with other RNA interference models. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=198 SRC="FIGDIR/small/494194v1_ufig1.gif" ALT="Figure 1"> View larger version (46K): org.highwire.dtl.DTLVardef@17e68e0org.highwire.dtl.DTLVardef@17855corg.highwire.dtl.DTLVardef@349482org.highwire.dtl.DTLVardef@1ef38_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioengineering↗